Literature DB >> 31867717

PLCε1 suppresses tumor growth by regulating murine T cell mobilization.

M Strazza1, K Adam1, A V Smrcka2, S Lerrer1, A Mor1.   

Abstract

Phospholipase C epsilon 1 (PLCε1) is a unique member of the phospholipase family, in that it also functions as a guanine nucleotide exchange factor (GEF) for the small GTPase Rap1. It is this function as a Rap1 GEF that gives PLCε1 an essential role in chemokine-mediated T cell adhesion. We have utilized a syngeneic tumor model, MC38 cells in C57BL/6 mice, and observed that tumors grow larger and more quickly in the absence of PLCε1. Single-cell analysis revealed an increased CD4+ /CD8+ ratio in the spleens, lymph nodes and tumors of PLCε1 knock-out tumor-bearing mice. T cells isolated from PLCε1 knock-out mice were less activated by multiple phenotypical parameters than those from wild-type mice. We additionally noted a decrease in expression of the chemokine receptors C-X-C chemokine receptor type 4 (CXCR4) and C-C motif chemokine receptor 4 (CCR4) on CD4+ T cells from the spleens, lymph nodes and tumors of PLCε1 knock-out mice compared to wild-type mice, and diminished migration of PLCε1-depleted CD3+ T cells towards stromal cell-derived factor (SDF)-1α. Based on these results, we conclude that PLCε1 is a potential regulator of tumor-infiltrating lymphocytes, functioning, at least in part, at the level of T cell trafficking and recruitment.
© 2020 British Society for Immunology.

Entities:  

Keywords:  MC38; SDF-1α; T cells; chemokines; murine cancer model; phospholipase C epsilon 1

Mesh:

Substances:

Year:  2020        PMID: 31867717      PMCID: PMC7066383          DOI: 10.1111/cei.13409

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

2.  Phospholipase C epsilon modulates beta-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy.

Authors:  Huan Wang; Emily A Oestreich; Naoya Maekawa; Tara A Bullard; Karen L Vikstrom; Robert T Dirksen; Grant G Kelley; Burns C Blaxall; Alan V Smrcka
Journal:  Circ Res       Date:  2005-11-17       Impact factor: 17.367

Review 3.  Overcoming hurdles in developing successful drugs targeting chemokine receptors.

Authors:  Thomas J Schall; Amanda E I Proudfoot
Journal:  Nat Rev Immunol       Date:  2011-04-15       Impact factor: 53.106

4.  CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile.

Authors:  Elena Sierra-Filardi; Concha Nieto; Angeles Domínguez-Soto; Rubén Barroso; Paloma Sánchez-Mateos; Amaya Puig-Kroger; María López-Bravo; Jorge Joven; Carlos Ardavín; José L Rodríguez-Fernández; Carmen Sánchez-Torres; Mario Mellado; Angel L Corbí
Journal:  J Immunol       Date:  2014-03-17       Impact factor: 5.422

5.  Phospholipase C epsilon (PLCε) induced TRPC6 activation: a common but redundant mechanism in primary podocytes.

Authors:  Hermann Kalwa; Ursula Storch; Jana Demleitner; Susanne Fiedler; Tim Mayer; Martina Kannler; Meike Fahlbusch; Holger Barth; Alan Smrcka; Friedhelm Hildebrandt; Thomas Gudermann; Alexander Dietrich
Journal:  J Cell Physiol       Date:  2015-06       Impact factor: 6.384

6.  Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease.

Authors:  Jing Zhang; Jan Romero; Audrey Chan; Jennifer Goss; Sabrina Stucka; Jason Cross; Brian Chamberlain; Mustafa Varoglu; Haoqun Chandonnet; Dominic Ryan; Blaise Lippa
Journal:  Bioorg Med Chem Lett       Date:  2015-06-18       Impact factor: 2.823

7.  Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.

Authors:  B G Feagan; W J Sandborn; G D'Haens; S D Lee; M Allez; R N Fedorak; U Seidler; S Vermeire; I C Lawrance; A C Maroney; C H Jurgensen; A Heath; D J Chang
Journal:  Aliment Pharmacol Ther       Date:  2015-09-23       Impact factor: 8.171

8.  Guidelines for the use of flow cytometry and cell sorting in immunological studies.

Authors:  Andrea Cossarizza; Hyun-Dong Chang; Andreas Radbruch; Mübeccel Akdis; Immanuel Andrä; Francesco Annunziato; Petra Bacher; Vincenzo Barnaba; Luca Battistini; Wolfgang M Bauer; Sabine Baumgart; Burkhard Becher; Wolfgang Beisker; Claudia Berek; Alfonso Blanco; Giovanna Borsellino; Philip E Boulais; Ryan R Brinkman; Martin Büscher; Dirk H Busch; Timothy P Bushnell; Xuetao Cao; Andrea Cavani; Pratip K Chattopadhyay; Qingyu Cheng; Sue Chow; Mario Clerici; Anne Cooke; Antonio Cosma; Lorenzo Cosmi; Ana Cumano; Van Duc Dang; Derek Davies; Sara De Biasi; Genny Del Zotto; Silvia Della Bella; Paolo Dellabona; Günnur Deniz; Mark Dessing; Andreas Diefenbach; James Di Santo; Francesco Dieli; Andreas Dolf; Vera S Donnenberg; Thomas Dörner; Götz R A Ehrhardt; Elmar Endl; Pablo Engel; Britta Engelhardt; Charlotte Esser; Bart Everts; Anita Dreher; Christine S Falk; Todd A Fehniger; Andrew Filby; Simon Fillatreau; Marie Follo; Irmgard Förster; John Foster; Gemma A Foulds; Paul S Frenette; David Galbraith; Natalio Garbi; Maria Dolores García-Godoy; Jens Geginat; Kamran Ghoreschi; Lara Gibellini; Christoph Goettlinger; Carl S Goodyear; Andrea Gori; Jane Grogan; Mor Gross; Andreas Grützkau; Daryl Grummitt; Jonas Hahn; Quirin Hammer; Anja E Hauser; David L Haviland; David Hedley; Guadalupe Herrera; Martin Herrmann; Falk Hiepe; Tristan Holland; Pleun Hombrink; Jessica P Houston; Bimba F Hoyer; Bo Huang; Christopher A Hunter; Anna Iannone; Hans-Martin Jäck; Beatriz Jávega; Stipan Jonjic; Kerstin Juelke; Steffen Jung; Toralf Kaiser; Tomas Kalina; Baerbel Keller; Srijit Khan; Deborah Kienhöfer; Thomas Kroneis; Désirée Kunkel; Christian Kurts; Pia Kvistborg; Joanne Lannigan; Olivier Lantz; Anis Larbi; Salome LeibundGut-Landmann; Michael D Leipold; Megan K Levings; Virginia Litwin; Yanling Liu; Michael Lohoff; Giovanna Lombardi; Lilly Lopez; Amy Lovett-Racke; Erik Lubberts; Burkhard Ludewig; Enrico Lugli; Holden T Maecker; Glòria Martrus; Giuseppe Matarese; Christian Maueröder; Mairi McGrath; Iain McInnes; Henrik E Mei; Fritz Melchers; Susanne Melzer; Dirk Mielenz; Kingston Mills; David Mirrer; Jenny Mjösberg; Jonni Moore; Barry Moran; Alessandro Moretta; Lorenzo Moretta; Tim R Mosmann; Susann Müller; Werner Müller; Christian Münz; Gabriele Multhoff; Luis Enrique Munoz; Kenneth M Murphy; Toshinori Nakayama; Milena Nasi; Christine Neudörfl; John Nolan; Sussan Nourshargh; José-Enrique O'Connor; Wenjun Ouyang; Annette Oxenius; Raghav Palankar; Isabel Panse; Pärt Peterson; Christian Peth; Jordi Petriz; Daisy Philips; Winfried Pickl; Silvia Piconese; Marcello Pinti; A Graham Pockley; Malgorzata Justyna Podolska; Carlo Pucillo; Sally A Quataert; Timothy R D J Radstake; Bartek Rajwa; Jonathan A Rebhahn; Diether Recktenwald; Ester B M Remmerswaal; Katy Rezvani; Laura G Rico; J Paul Robinson; Chiara Romagnani; Anna Rubartelli; Beate Ruckert; Jürgen Ruland; Shimon Sakaguchi; Francisco Sala-de-Oyanguren; Yvonne Samstag; Sharon Sanderson; Birgit Sawitzki; Alexander Scheffold; Matthias Schiemann; Frank Schildberg; Esther Schimisky; Stephan A Schmid; Steffen Schmitt; Kilian Schober; Thomas Schüler; Axel Ronald Schulz; Ton Schumacher; Cristiano Scotta; T Vincent Shankey; Anat Shemer; Anna-Katharina Simon; Josef Spidlen; Alan M Stall; Regina Stark; Christina Stehle; Merle Stein; Tobit Steinmetz; Hannes Stockinger; Yousuke Takahama; Attila Tarnok; ZhiGang Tian; Gergely Toldi; Julia Tornack; Elisabetta Traggiai; Joe Trotter; Henning Ulrich; Marlous van der Braber; René A W van Lier; Marc Veldhoen; Salvador Vento-Asturias; Paulo Vieira; David Voehringer; Hans-Dieter Volk; Konrad von Volkmann; Ari Waisman; Rachael Walker; Michael D Ward; Klaus Warnatz; Sarah Warth; James V Watson; Carsten Watzl; Leonie Wegener; Annika Wiedemann; Jürgen Wienands; Gerald Willimsky; James Wing; Peter Wurst; Liping Yu; Alice Yue; Qianjun Zhang; Yi Zhao; Susanne Ziegler; Jakob Zimmermann
Journal:  Eur J Immunol       Date:  2017-10       Impact factor: 6.688

Review 9.  Clinical significance of tumor-infiltrating lymphocytes in breast cancer.

Authors:  Sasha E Stanton; Mary L Disis
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751

Review 10.  Enhancement of T cell recruitment and infiltration into tumours.

Authors:  C Oelkrug; J M Ramage
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

View more
  1 in total

Review 1.  The Complexity of Targeting Chemokines to Promote a Tumor Immune Response.

Authors:  Marianne Strazza; Adam Mor
Journal:  Inflammation       Date:  2020-08       Impact factor: 4.657

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.